Ph-like ALL, for example, often has mutations in JAK2 and IKZF1, particularly in cases where a CRLF2 rearrangement is also present.20,47 These additional mutations can indicate a more aggressive cancer that may be responsive to therapies other than the standard of care.48 This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.